A highly structured pharmaceutical market.
Tunisia is an attractive pharmaceutical market, combining a stable regulatory environment, growing healthcare demand, and broad patient access to treatment. Valued at approximately €1.24 billion, it is supported by over 2,400 pharmacies, more than 300 healthcare institutions, and the National Health Insurance Fund (CNAM), which covers a wide range of therapeutic areas, including oncology, chronic diseases, and rare diseases.
What makes the market relevant
Strategic Location
Tunisia benefits from close proximity to European markets, strong trade partnerships, and efficient logistics networks, making it a strategic hub for pharmaceutical business development.
Strong Public Healthcare Demand
Driven by growing healthcare demand and public investment, Tunisia offers attractive opportunities for international pharmaceutical manufacturers. The PCT procures significant volumes each year, including innovative and specialty medicines across multiple therapeutic areas.
Established Regulatory Framework
Tunisia benefits from a well-established pharmaceutical regulatory framework, with clear pathways for product registration and market authorization, supported by robust pharmacovigilance standards.
Qualified Healthcare Ecosystem
Tunisia hosts one of the most developed pharmaceutical ecosystems in Africa, with strong private and public healthcare infrastructure.
Explore Your Market Entry Options
Whether you're entering Tunisia for the first time or looking to expand your commercial footprint, we can help.